MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318796 | Name: Telbivudine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance. Telbivudine is a synthetic thymidine nucleoside analogue; it is the L-isomer of thymidine.

Chemical Structure

Telbivudine
Telbivudine
CAS#3424-98-4

Theoretical Analysis

MedKoo Cat#: 318796

Name: Telbivudine

CAS#: 3424-98-4

Chemical Formula: C10H14N2O5

Exact Mass: 242.0903

Molecular Weight: 242.23

Elemental Analysis: C, 49.58; H, 5.83; N, 11.56; O, 33.02

Price and Availability

Size Price Availability Quantity
25mg USD 450.00
50mg USD 850.00
100mg USD 1,250.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
LDT 600; LD-T600; LDT600; Telbivudine; Tyzeka; Epavudine
IUPAC/Chemical Name
1-((2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione
InChi Key
IQFYYKKMVGJFEH-CSMHCCOUSA-N
InChi Code
InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1
SMILES Code
O=C1NC(C(C)=CN1[C@@H]2C[C@H]([C@H](CO)O2)O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 242.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Oct;25(8):653-82. PMID: 14671684. 2: Hodge RA. Telbivudine/Torcitabine Idenix/Novartis. Curr Opin Investig Drugs. 2004 Feb;5(2):232-41. PMID: 15043399. 3: Lok AS. New treatment of chronic hepatitis B. Semin Liver Dis. 2004;24 Suppl 1:77-82. doi: 10.1055/s-2004-828682. PMID: 15192805. 4: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Jul-Aug;26(6):473-503. PMID: 15349141. 5: Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, Yuen MF, Chao GC, Myers MW. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004 Sep;40(3):719-26. doi: 10.1002/hep.20374. PMID: 15349912. 6: Delaney WE 4th, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother. 2004 Oct;48(10):3702-10. doi: 10.1128/AAC.48.10.3702-3710.2004. PMID: 15388423; PMCID: PMC521873. 7: Hadziyannis SJ, Papatheodoridis GV. Emerging treatments in chronic hepatitis B. Expert Opin Emerg Drugs. 2004 Nov;9(2):207-21. doi: 10.1517/14728214.9.2.207. PMID: 15571480. 8: Fung SK, Lok AS. Management of hepatitis B patients with antiviral resistance. Antivir Ther. 2004 Dec;9(6):1013-26. PMID: 15651760. 9: Arosemena LR, Cortes RA, Servin L, Schiff ER. Current and future treatment of chronic hepatitis B. Minerva Gastroenterol Dietol. 2005 Mar;51(1):77-93. PMID: 15756148. 10: Han SH. Telbivudine: a new nucleoside analogue for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2005 Apr;14(4):511-9. doi: 10.1517/13543784.14.4.511. PMID: 15882124. 11: Marcellin P, Asselah T, Boyer N. Traitement de l'hépatite chronique B [Treatment of chronic hepatitis B]. Rev Prat. 2005 Mar 31;55(6):624-32. French. PMID: 15913114. 12: Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat. 2005 Jul;12(4):333-45. doi: 10.1111/j.1365-2893.2005.00599.x. PMID: 15985003. 13: Buti M, Esteban R. Drugs in development for hepatitis B. Drugs. 2005;65(11):1451-60. doi: 10.2165/00003495-200565110-00001. PMID: 16033287. 14: Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA; Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005 Aug;129(2):528-36. doi: 10.1016/j.gastro.2005.05.053. PMID: 16083710. 15: Gish RG. Clinical trial results of new therapies for HBV: implications for treatment guidelines. Semin Liver Dis. 2005;25 Suppl 1:29-39. doi: 10.1055/s-2005-915648. PMID: 16103979. 16: Yuen MF, Lai CL. Telbivudine: an upcoming agent for chronic hepatitis B. Expert Rev Anti Infect Ther. 2005 Aug;3(4):489-94. doi: 10.1586/14787210.3.4.489. PMID: 16107194. 17: Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther. 2005;10(5):625-33. PMID: 16152756. 18: Dienstag JL. Looking to the future: new agents for chronic hepatitis B. Am J Gastroenterol. 2006;101 Suppl 1:S19-25. doi: 10.1111/j.1572-0241.2006.00377.x. PMID: 16448448. 19: Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J. 2006 Feb;36(2):100-13. doi: 10.1111/j.1445-5994.2006.01027.x. PMID: 16472264. 20: Zhou XJ, Lloyd DM, Chao GC, Brown NA. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol. 2006 Mar;46(3):275-81. doi: 10.1177/0091270005284849. PMID: 16490803.